Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What Is The Current Size And Growth Outlook For The Retinal Biologics Market?

The market size for retinal biologics has been experiencing swift expansion lately. It is projected to rise from $25.17 billion in 2024 to $28.12 billion in 2025, marking a compound annual growth rate (CAGR) of 11.7%. The surge in the past period is primarily credited to the surge in retinal disorder cases, an increasingly aging demographic, heightened awareness and preliminary diagnosis, the development of healthcare infrastructures, and escalated healthcare spending.

Over the upcoming years, the size of the retinal biologics market is predicted to experience a swift expansion. It is projected to inflate to “$43.55 billion by 2029 with a Compound Annual Growth Rate (CAGR) of 11.6%. The surge during the forecasted period can be credited to the broadening of therapeutic applications, the emergence of personalized medicine, the progress of emerging markets, a robust biologics pipeline, collaborations, and partnerships, as well as governmental initiatives and backing. Major trends during the forecasted period consist of the adoption of non-invasive delivery techniques, the application of real-world evidence, expanded indications, streamlining of regulatory pathways, and the focus on patient-centered outcomes.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11911&type=smp

Which Demand Drivers Are Strengthening The Retinal Biologics Market?

The retinal biologics market is expected to expand due to the escalating prevalence of diabetic eye disease. This condition results from diabetes, leading to vision loss and blindness in diabetic patients. Retinal biologics provide specific and efficient treatment opportunities, enabling early intervention and better prevention of vision loss as a result of diabetic eye disease. For example, data from the Australian Bureau of Statistics in December 2023 showed that in 2022, roughly 1.3 million individuals, which represent 5.3% of the Australian population, were diabetic. This number reflects a significant increase from 3.3%. Consequently, the growing occurrence of diabetic eye disease is fueling the expansion of the retinal biologics market.

Which Segment Accounts For The Largest Share In The Retinal Biologics Market?

The retinal biologics market covered in this report is segmented –

1) By Drug Class: Vascular Endothelial Growth Factor (VEGF)-A Antagonist, Tumor Necrosis Factor (TNF)-A Inhibitor

2) By Indication: Macular Degeneration, Diabetic Retinopathy, Uveitis, Diabetic Macular Edema, Other Indications

3) By Distribution Channel: Hospitals, Pharmacies, Specialty Clinics, Online Pharmacies, Other Distribution Channels

Subsegments:

1) By Vascular Endothelial Growth Factor (VEGF)-A Antagonist: Monoclonal Antibodies, Small Molecule Inhibitors

2) By Tumor Necrosis Factor (TNF)-A Inhibitor: Monoclonal Antibodies, Fusion Proteins

Which Long-Term Trends Will Play A Crucial Role In The Retinal Biologics Market?

The trend of product innovation is gaining traction in the retinal biologics market. Leading companies in this industry are capitalizing on the creation of unique products to solidify their market standing and outdo their competitors. For example, in May 2023, F. Hoffmann-La Roche Ltd., a Swiss healthcare firm, received approval from the U.S. Food and Drug Administration for its supplemental biologics license application (sBLA) for Vabysmo (faricimab), developed for treating macular edema after retinal vein occlusion (RVO). The approval was obtained on the grounds of two Phase III trials that showcased early and sustained vision enhancement with Vabysmo, satisfying the primary target of non-inferiority to aflibercept. This product is deemed as the first bispecific antibody authorized for ocular use in the treatment of ‘wet’ age-related macular degeneration and diabetic macular edema. Additionally, additional research indicated the lack of blood vessel leakage in the retina amongst Vabysmo users in contrast to aflibercept users.

Which Players Are Shaping The Competitive Landscape Of The Retinal Biologics Market?

Major companies operating in the retinal biologics market include Regeneron Pharmaceuticals Inc., AbbVie Inc., MeiraGTx Limited, Oxurion NV, Novartis AG, Amgen Inc., Spark Therapeutics Inc., Bayer AG, Bausch Health Companies Inc., Merck & Co. Inc., Santen Pharmaceutical Co. Ltd., Pfizer Inc., Boehringer Ingelheim, Eyenovia Inc., EyePoint Pharmaceuticals Inc., Iveric Bio Inc., Kodiak Sciences Inc., Aerie Pharmaceuticals Inc., Alimera Sciences Inc., Ocular Therapeutix Inc., Acucela Inc., Clearside Biomedical Inc., Ophthotech Corporation, Xcovery Holdings, Athenex Inc., Fidia Farmaceutici S.p.A, Eton Pharmaceuticals Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/retinal-biologics-global-market-report

What Regional Factors Are Accelerating Growth In The Retinal Biologics Market?

North America was the largest region in the retinal biologics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the retinal biologics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=11911&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model